Application Areas
Blood Stream
Clinically proven for blood applications
Bactiguard® is the only coating developed to reduce hospital associated infections, that has also received regulatory approval for use on medical devices in both the urinary tract and the blood stream.
The development of coated central venous catheters (CVC) led to a product with CE class III approval on the European market based on excellent clinical and in vivo/in vitro data. The clinical studies showed that the coating significantly reduced the incidence of catheter related infections with approximately 50% after thirteen days without an increase in the incidence of thrombosis1,2.
Reduction of the incidence of catheter-related infections for central venous catheter in oncological patients. The investigation included 266 patients, 113 received standard uncoated catheters and 120 Bactiguard® coated catheters1.
Toxicological testing shows that the antimicrobial property of the Bactiguard® coating is not achieved at the expense of its biocompatibility3.
- Mouse fibroblasts; extracts from the Bactiguard® coated catheter did not show cytotoxic reactions.
- Short and long term implantation studies; no differences in biological reactions compared to control.
- Hemocompatibility; no tendency of increased platelet adhesion due to the Bactiguard® coating
References
1 Goldschmidt H. et al., Prevention of catheter-related infections by silver coated central venous catheter in oncological patients. Zentralbl Bakteriol. 1995; 283:215-223
2 Harter C. et al., Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy. Cancer. 2002; 94:245-251
3 Jansen B. et al., In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J Biomat Appl. 1994; 9:55-70